Acer Therapeutics (ACER) May See a Boost From Publication of NaPB Utility on Top of Acute MSUD- Roth Capital
Tweet Send to a Friend
Roth Capital analyst Jonathan Aschoff reiterated a Buy rating and $10.00 price target on Acer Therapeutics (NASDAQ: ACER) after a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
